Analysis of an experimental murine model of melanoma after vaccination protocols with induction of immunogenic cell death.
Melanoma; Therapeutic vaccine; Prophylactic Vaccine; B16 cells; Immunogenic death.
Melanoma is a malignant skin cancer that has a high rate of metastasis and mortality, being a significant socioeconomic problem due to the high cost of treatment and patient follow-up. The incidence of this disease is rapidly increasing and is more common in Caucasian people, mainly affecting young and middle-aged individuals. Melanoma arises from mutations in melanocytes, cells responsible for skin pigmentation, and can be cutaneous or mucosal, the former being more common and presenting a better prognosis. Genetic and environmental factors influence the development of melanoma, and available treatments include chemotherapy, targeted therapies, and immunotherapy. However, the rapid advance and aggressiveness of melanoma represent challenges in treatment, highlighting the need for studies and improvement of therapeutic approaches. The use of therapeutic vaccines, which activate the immune system against the tumor, has shown promise in the treatment of resistant tumors, including melanoma, providing an effective alternative with fewer side effects compared to conventional treatments. In this work we analyze the role of immune activation made from vaccination with tumor cells in immunogenic death. This treatment can be done before or after the appearance of the tumor and has demonstrated a decrease in tumor growth when compared to groups treated with vaccines made with cells killed by necrosis. The in vitro and ex vivo analyzes need to be improved to elucidate the mechanism that generates the results already found.